2022
DOI: 10.1080/1120009x.2022.2051128
|View full text |Cite
|
Sign up to set email alerts
|

Amoxicillin-associated Stevens-Johnson syndrome or toxic epidermal necrolysis: systematic review

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

1
1
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 74 publications
1
1
0
Order By: Relevance
“…Um et al found that the latency period in antibiotic-induced DRESS was significantly shorter than in anticonvulsant-induced DRESS( Um et al, 2010 ). Drug-related skin changes generally begin to appear after 1–3 weeks of continuous drug use, and the latent period for cutaneous adverse drug reactions with SJS/TEN phenotype in this study was 8.5 days on average, which was consistent with recent reports ( Lee et al, 2023 ; Pejcic et al, 2023 ).…”
Section: Discussionsupporting
confidence: 92%
See 1 more Smart Citation
“…Um et al found that the latency period in antibiotic-induced DRESS was significantly shorter than in anticonvulsant-induced DRESS( Um et al, 2010 ). Drug-related skin changes generally begin to appear after 1–3 weeks of continuous drug use, and the latent period for cutaneous adverse drug reactions with SJS/TEN phenotype in this study was 8.5 days on average, which was consistent with recent reports ( Lee et al, 2023 ; Pejcic et al, 2023 ).…”
Section: Discussionsupporting
confidence: 92%
“…Amoxicillin (AMX) is among the most prescribed and the best tolerated antimicrobials worldwide ( Sharland et al, 2018 ). However, AMX is also one of the most common drug allergy labels in the electronic health record, it can occasionally trigger severe cutaneous adverse reactions (SCAR), such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reactions with eosinophilia and systemic symptoms (DRESS), and drug-induced acute erythroderma, with a significant morbidity and mortality ( Aouam et al, 2010 ; Girelli et al, 2013 ; Pejcic et al, 2023 ). In time of the development of SCAR in combination medicines and antibiotic resistant settings, future exposure to all concurrently dosed drugs is contraindicated, seriously restricting the choice of candidate drugs for the patients ( Sodhi et al, 2023 ).…”
Section: Introductionmentioning
confidence: 99%